FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPRO	VAL				
	OMB Number:	3235-0287				
l	Estimated average burde	en				
l	hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Brooks Michael J  (Last) (First) (Middle)  C/O EDESA BIOTECH INC.  100 SPY COURT						2. Issuer Name and Ticker or Trading Symbol Edesa Biotech, Inc. [ EDSA ]  3. Date of Earliest Transaction (Month/Day/Year) 01/08/2020									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify below)  President  6. Individual or Joint/Group Filing (Check Applicable				
(Street)  MARKHAM A6  L3R 5H6  (City) (State) (Zip)				- 4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)									X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						ction 2A. Deemed Execution Date,			3. Transa Code (	ction		ties Acqu	ired (A	A) or	5. Amou Securitie Benefici	int of es ally Following	Form (D) or	: Direct c r Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares 01/08/						2020			Code	v	Amount 1,827	(A) (D)		Price 54.11 <sup>(1</sup>	Transac (Instr. 3	Transaction(s) (Instr. 3 and 4)		D	
		Т	able II -						uired, D s, optior						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		n of		6. Date Exercisa Expiration Date (Month/Day/Year		Amou Secu Unde Deriv		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	or Nui of	mber ares					
Common Share Warrants (Right to Buy) <sup>(2)</sup>	\$4.8	01/08/2020			P		1,371		07/08/202	0 0	7/08/2023	Commo Shares	1,	371	(1)	1,371		D	
Common Share Warrants (Right to	\$4	01/08/2020			P		914		07/08/202	0 1	1/08/2020	Commo Shares	9	014	(1)	914		D	

## **Explanation of Responses:**

- 1. The reported securities are included within 1,371 Common Shares purchased by the reporting person for \$4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share
- 2. Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023.
- 3. Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020.

01/10/2020 /s/ Michael J. Brooks

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.